Insider Selling: Clover Health Investments (NASDAQ:CLOV) CEO Sells 175,000 Shares of Stock

Key Points

• CEO Brady Patrick Priest sold 175,000 shares at an average price of $2.17 on March 4, reducing his direct stake by about 8% and generating roughly $379,750 in proceeds.
• Clover is the first payer live on a CMS Aligned Network/TEFCA, an operational milestone that improved access to real‑time clinical and claims data and was cited as the catalyst for a near‑term stock jump.
• Financials are mixed: revenue beat estimates ($487.7M vs $467.1M) but EPS missed (loss of $0.10 vs. -$0.05), the company has negative margins and ROE, and analysts show a consensus "Hold" with a $3.07 price target after several divergent ratings.

Clover Health Investments, Corp. (NASDAQ:CLOV - Get Free Report) CEO Brady Patrick Priest sold 175,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $2.17, for a total transaction of $379,750.00. Following the completion of the transaction, the chief executive officer owned 1,998,584 shares in the company, valued at $4,336,927.28. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Clover Health Investments Stock Down 4.2%

CLOV stock traded down $0.09 during midday trading on Thursday, reaching $2.07. The company's stock had a trading volume of 3,940,209 shares, compared to its average volume of 6,099,688. The business's 50-day simple moving average is $2.31 and its 200-day simple moving average is $2.62. Clover Health Investments, Corp. has a 52 week low of $1.93 and a 52 week high of $3.92. The stock has a market cap of $1.07 billion, a PE ratio of -12.18 and a beta of 2.15.

Clover Health Investments (NASDAQ:CLOV - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.05). Clover Health Investments had a negative net margin of 4.45% and a negative return on equity of 25.17%. The company had revenue of $487.71 million during the quarter, compared to analyst estimates of $467.06 million. As a group, equities analysts forecast that Clover Health Investments, Corp. will post -0.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded Clover Health Investments from a "sell" rating to a "hold" rating in a research report on Sunday, February 15th. Canaccord Genuity Group restated a "buy" rating and set a $3.70 price objective on shares of Clover Health Investments in a report on Tuesday, January 20th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Clover Health Investments in a research note on Monday, December 29th. Zacks Research lowered shares of Clover Health Investments from a "strong-buy" rating to a "hold" rating in a report on Monday, November 24th. Finally, Leerink Partners decreased their price target on shares of Clover Health Investments from $3.00 to $2.50 and set a "market perform" rating for the company in a report on Thursday. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $3.07.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CLOV. Abel Hall LLC bought a new stake in shares of Clover Health Investments during the fourth quarter worth $27,000. Clarity Wealth Advisors LLC acquired a new position in Clover Health Investments in the 2nd quarter worth $28,000. Allworth Financial LP increased its holdings in Clover Health Investments by 218.9% during the 3rd quarter. Allworth Financial LP now owns 9,509 shares of the company's stock worth $29,000 after purchasing an additional 6,527 shares in the last quarter. Quadrature Capital Ltd bought a new position in Clover Health Investments during the 4th quarter worth about $29,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Clover Health Investments in the 4th quarter valued at about $29,000. Institutional investors and hedge funds own 19.77% of the company's stock.

Key Headlines Impacting Clover Health Investments

Here are the key news stories impacting Clover Health Investments this week:

• Positive Sentiment: Clover announced a collaboration with Kno2 and became the first payer live on a CMS Aligned Network and TEFCA — a meaningful operational milestone that improves Clover's access to real‑time clinical and claims data and was cited as the catalyst for a near-term stock jump. Clover Health Moves from Pledge to Production
• Positive Sentiment: Market coverage noted an ~8% move after the CMS Aligned Network news, showing that the announcement produced immediate positive investor reaction. Clover Health Enters Collaboration to Be Part of CMS Aligned Network
• Neutral Sentiment: An analyst piece recommends retaining the stock due to 38% Medicare Advantage membership growth and rising EBITDA but flags higher medical costs and policy risk as margin headwinds — a mixed view that supports cautious, not aggressive, buying. Here's Why You Should Retain Clover Stock in Your Portfolio for Now
• Neutral Sentiment: Short-interest reports in recent entries show zero shares / NaN changes and a 0.0 days-to-cover metric — data appears erroneous or not meaningful, so short-interest is not a clear driver today.
• Negative Sentiment: CEO Brady Patrick Priest sold 175,000 shares at an average $2.17 (about $379,750), reducing his direct stake by ~8%. Insider sales can prompt investor concern about near-term conviction. SEC Form 4 - Brady Patrick Priest
• Negative Sentiment: Leerink Partners trimmed its price target from $3.00 to $2.50 and moved to a "market perform" rating — a downgrade that reduces analyst upside and may pressure momentum despite the company’s operational wins. Leerink Lowers Price Target

About Clover Health Investments

Clover Health Investments is a technology-driven healthcare company specializing in Medicare Advantage plans for senior populations. The company combines insurance coverage with a proprietary software platform to improve care coordination, outcomes tracking and cost management. By leveraging data analytics, Clover Health aims to deliver personalized care pathways and preventive interventions for its members.

At the core of Clover's offering is its Clover Assistant platform, which aggregates clinical and claims data from multiple sources to create real-time insights for physicians and care teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.